Overview

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation

Status:
Active, not recruiting

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

Multicentric phase II trial to evaluate efficacy and safety of ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients with refractory/relapsed non-GCB DLBCL non candidates to autologous stem-cell transplantation (ASCT) An extensive biological study will be conducted in order to further characterize this population of DLBCL patients and correlate the response obtained with the biological profile of the tumor.

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Collaborator:

Janssen-Cilag, S.A.

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Gemcitabine
Oxaliplatin
Rituximab